Antipsychotics can reduce the intensity, frequency or impact of hallucinations, delusions and disorganised thinking. Improvement may involve feeling less threatened or less compelled to act on an experience before its content fully changes. Some medicines also have evidence for particular mood-related indications, but these benefits should not be generalised to every drug.
Antipsychotics are medicines used to treat psychotic symptoms and, for some drugs, other conditions. Most established agents act through dopamine D2 receptors, with substantial differences in additional targets and pharmacology. Benefits and adverse effects vary between medicines and individuals, so treatment is assessed through observed outcomes rather than the drug’s label alone.
Response varies, and treatment does not reliably resolve all negative or cognitive symptoms. Reduced agitation or increased sleepiness is not the same as relief from psychosis. Assessment should ask which experiences have improved and whether daily life is becoming more manageable. Benefits may develop over different time scales. A useful evaluation includes distress, functioning and adverse effects, rather than treating a quieter presentation or lower symptom score as the only sign that treatment is working well.
Treatment goals can be specified before a trial, such as reduced fear, fewer interruptions from voices or better ability to complete ordinary activities. Tracking these outcomes makes benefit more visible and review more precise. The person’s priorities should remain part of the assessment, particularly when a symptom score improves but side effects or practical difficulties limit the value of that change.
Further reading: National Institute of Mental Health; Research record 10739409; DailyMed prescribing information.
Comments are closed, but trackbacks and pingbacks are open.